Skip Navigation


European Heart Journal Advance Access originally published online on April 7, 2006
European Heart Journal 2006 27(14):1651-1656; doi:10.1093/eurheartj/ehi841
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/14/1651    most recent
ehi841v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sleight, P.
Right arrow Articles by Zannad, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sleight, P.
Right arrow Articles by Zannad, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Benefits, challenges, and registerability of the polypill

Peter Sleight*, Hubert Pouleur and Faiez Zannad

Cardiac Department, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK

Received 29 August 2005; revised 3 March 2006; accepted 9 March 2006; online publish-ahead-of-print 7 April 2006.

* Corresponding author. Tel: +44 186 576 0564; fax: +44 186 576 8844. E-mail address: peter.sleight{at}attglobal.net

Guidelines for the management of cardiovascular disease (CVD) stress the importance of treating global risk, rather than individual risk, factors. Patients at high cardiovascular (CV) risk, for example, benefit from a combination of aspirin, antihypertensive agents, lipid-lowering drugs, and possibly folic acid. As the number of medications that a patient requires increases, adherence and compliance to therapy are likely to decrease. The use of affordable, multiple-target, fixed-combination ‘polypills’, which concomitantly reduce multiple risk factors without increasing the pill burden or the risk of adverse effects, has the potential to improve CV risk factor management, thereby reducing the incidence of CVD. This review discusses the benefits of the polypill and the challenges and requirements for its success and registerability. Discussions with regulatory bodies are required in order to obtain some ‘balance’ between an overcautious registration approach and the potentially large public health benefits that are likely to arise from the use of polypills.

Key Words: Cardiovascular disease • Polypill • Hypertension • Dyslipidaemia • Registration


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
J. A. Levine and R. M. Davis
The Pol-e-Pill Finally Arrives
Diabetes, July 1, 2008; 57(7): 1784 - 1785.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
A. O. Stirban and D. Tschoepe
Should We Be More Aggressive in the Therapy Against Cardiovascular Risk Factors?: Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?
Diabetes Care, February 1, 2008; 31(Supplement_2): S226 - S228.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. A. Preston, P. Harvey, O. Herfert, G. Dykstra, J. W. Jukema, F. Sun, and D. Gillen
A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacodynamic Interaction of Coadministered Amlodipine and Atorvastatin in 1660 Patients With Concomitant Hypertension and Dyslipidemia: The Respond Trial
J. Clin. Pharmacol., December 1, 2007; 47(12): 1555 - 1569.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.